Introduction
Stage IV advanced gastric cancer with peritoneal dissemination and multiple liver metastases has a grave prognosis. Most patients with such tumors undergo palliative surgery to relieve gastrointestinal obstruction and receive systemic chemotherapy in an attempt to prolong survival (Kondo, Murase et al., 1996; Ogawa, Maki et al., 1999; Mori, Masaki et al., 1999; Shinkai, Kida et al., 1999) . As chemotherapy for advanced gastric cancer, regimens based on 5-fluorouracil (5-FU) are often used, such as 5-FU + cisplatin (CDDP), 5-FU + methotrexate, and 5-FU + leucovorin (LV) (Konishi, Hirishi et al., 1994; Hsu, Yeh et al., 1997; Iwamoto, Kimoto et al., 1998; Perez, Lacava et al., 1998; Kim, Murakami et al., 1999; Chen, Liu et al., 1999; Enjoji and the Nagasaki Digestive Organ Cancer Chemotherapy Study Group; . In Japan, postoperative adjuvant therapy with 5-FU and low-dose CDDP as the modulator is often performed as first-line chemotherapy (Kondo, Murase et al., 1996; Ogawa, Maki et al., 1999; Mori, Masaki et al., 1999 , Shinkai, Kida et al., 1999 .
Recently, to improve the response to oral fluoropyrimidines that are widely used after intravenous consolidation therapy in Japan and to allow ambulatory follow-up of elderly patients, several new-generation oral fluoropyrimidine preparations such as TS-1 and Orzel have been developed for use in combination with oral modulators. TS-1 (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan)
was developed for the treatment of gastric cancer by combining tegafur with gimeracil (CDHP), which is a dihydropyrimidine dehydrogenase (DPD)-inhibiting fluoropyrimidine, and oteracil potassium (Oxo) to control the gastrointestinal toxicity of 5-FU. Orzel (Taiho Pharmaceutical Co., Ltd., Tokyo, Japan) is a combination of tegafur/uracil (UFT) with LV, which is indicated for the treatment of colorectal cancer. Several reports on the efficacy of these newer preparations have been published (Sakata, Ohtsu et al., 1998; Sugimachi, Maehara et al., 1999; Koizumi, Kurihara et al., 2000; Mukai, Moriya et al., 2001 ).
We encountered a patient with stage IV advanced gastric cancer, who had peritoneal dissemination and lymph node involvement, and who developed two new liver metastases at 4 months after surgery. The patient received first-line treatment with low-dose CDDP+5FU, followed by oral outpatient maintenance therapy with TS-1+LV as a modulator. At 2 years and 10 months after surgery, this patient is currently disease-free, without ascites or any signs of recurrent liver metastasis. Here we report the details of this case in which stage IV gastric cancer responded to intravenous consolidation therapy plus outpatient maintenance therapy using a next-generation oral fluoropyrimidine preparation. 19-9, 14.6 (<37)ng/ml. There were no significant abnormalities of these findings, including the tumor markers.
Barium contrast radiography: A protruding Borrmann type II lesion with a diameter of 8 cm was observed to arise from the posterior wall of the greater curvature in the gastric body.
The tumor seemed to involve the greater omentum and the transverse mesocolon, but the duodenum and transverse colon were apparently unaffected ( Figure 1 ).
Gastroscopy: A protruding and ulcerated mass was located on the posterior wall of the greater curvature in the gastric body. Biopsy of this lesion gave a diagnosis of poorly differentiated adenocarcinoma.
Colonoscopy: No mucosal abnormalities of the transverse colon were observed, and there were no macroscopic lesions in the large intestine.
Abdominal ultrasonography:
There was a fist-sized tumor in the gastric body on the greater curvature, as well as a small volume of ascites in the peritoneal cavity. The boundaries of the tumor with the transverse mesocolon and the pancreas were relatively well defined, suggesting that other organs were not involved by direct invasion.
Abdominal magnetic resonance imaging: A fist-sized tumor was observed on the greater curvature of the stomach in the gastric body. Although involvement of the greater omentum was strongly suspected, the boundaries between the tumor and the transverse mesocolon or the pancreas were relatively clear, suggesting that there was no direct invasion of these organs.
Preoperative surgical diagnosis: Based on these results, the patient was diagnosed as having stage III advanced gastric cancer with ascites and metastasis to Group 1 lymph nodes around the stomach. The patient and his family were provided with an explanation of the disease, after which he gave informed consent to surgical resection and subsequent chemotherapy. Accordingly, total gastrectomy with D2 lymph node resection and splenectomy were performed on December 15, 2000 (Figure 2 ).
Findings at laparotomy: There was a fist-sized tumor on the greater curvature in the body of the stomach and the greater omentum was involved by the lesion. There was a hard, white nodule (10mm in diameter) in the greater omentum that was separate from the (500mg/m2 as a 24-hr continuous intravenous infusion) were given on 5 consecutive days per week for 2 weeks per month followed by a 2-week drug holiday as one course ( Figure   5 ). In July 2001, after three courses of this treatment had been completed, the metastases in segments 7 and 8 of the liver were almost eliminated along with the ascites on CT and MRI ( Figure 6 ). A total of six courses were given over about 6 months. There were no significant adverse reactions, such as alopecia, anorexia, or laboratory abnormalities (leukopenia, thrombocytopenia, or renal dysfunction). However, prominent skin pigmentation was noted. Before the 7th course of chemotherapy, the patient stated that he wanted to cease inpatient therapy and take oral anticancer drugs on an outpatient basis instead. Therefore, maintenance therapy was started with oral TS-1 (80mg/day)+LV (30 mg/day). The drugs were administered daily for 4 weeks followed by a 2-week drug holiday, so a total of 6 weeks was required per course. During the 4th week of this treatment, however, severe diarrhea developed. Accordingly, the dose of LV was reduced to 20mg/day and the schedule was changed to 2 weeks of treatment followed by a 2-week drug holiday (a total of 4 weeks per course) (Figure 7 ). Figure 7 . Schedule for oral maintenance therapy with 2 weeks of TS-1 plus leucovorin (LV) and a 2-week drug holiday (4 weeks per course).
At about 2 years and 10 months after surgery, the patient is still receiving this treatment on an outpatient basis without any signs of recurrence, including ascites, new liver metastases, or increased levels of tumor markers.
Discussion
The response rate to 5-FU or CDDP alone has been reported to be about 20%, while treatment with 5-FU plus CDDP increases the response rate to 30-40% or more (Ohtsu, Yoshida et al., 1991; Lacave, Baron et al., 1991; Cohn, Tester et al., 1998) . The antitumor effect of 5-FU depends on inhibition of DNA synthesis by the formation of a ternary complex between FdUMP (a metabolite of 5-FU), methylenetetrahydrofolate (CH2FH4), and thymidylate synthase (TS), leading to the inactivation of TS (Hsu, Yeh et al., 1997; Kim, Murakami et al., 1999; Chen, Liu et al., 1999) . On the other hand, CDDP blocks the uptake of methionine by cells in addition to inhibition of DNA synthesis. If intracellular and promotes that antitumor effect of 5-FU. Low-dose CDDP is less likely to cause adverse reactions; it promotes apoptotic cell death through a receptor signaling pathway even in the absence of intracellular free platinum, while the increase of folate metabolites due to CDDP and stimulation of a non-receptor signaling pathway by 5-FU are reported to facilitate the apoptotic death of gastric carcinoma cells (Kim, Tanabe et al., 2002) .
Intermittent administration of 5-FU has been reported to reduce its toxicity (Terashima, Irinoda et al., 2003) . Although a higher response rate can be achieved, patients are often hospitalized for long periods because 24-hr infusion must be continued for 4-6 weeks (Kondo, Murase et al., 1996; Ogawa, Maki et al., 1999; Mori, Masaki et al., 1999; Shinkai, Kida et al., 1999) . Accordingly, we modified the regimen to give at least six courses in order to compensate for shortening the duration of administration to 2 weeks per month.
Despite the relatively sustained duration of administration (2 weeks per month), there were no adverse effects such as myelosuppression, renal dysfunction, or diarrhea throughout the treatment period. However, the patient developed prominent brown pigmentation of the face, fingers, and forearms, which was probably caused by the impact of 5-FU on epidermal keratinocytes and prickle cells.
TS-1 was developed by combining tegafur with gimeracil (CDHP), which is a dihydropyrimidine dehydrogenase (DPD)-inhibiting fluoropyrimidine, and oteracil potassium (Oxo) to minimize the gastrointestinal toxicity of 5-FU. This is a new-generation fluoropyrimidine preparation with double modulation. Our patient was given oral chemotherapy with triple-modulation by adding LV, and this may be the most powerful combination available and seems promising as a next-generation oral fluoropyrimidine regimen that is stronger than Orzel (UFT+LV). However, when the standard 6-week course of this therapy (4 weeks of treatment plus a 2-week drug holiday) was attempted, severe diarrhea developed during the 4th week. After the regimen was modified to 2 weeks of treatment followed by a 2-week drug holiday, few adverse effects were noted and outpatient treatment has since been continued for more than 1.5 years. In Japan, the national health insurance system has only approved this regimen for gastric 
